##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 6 (2025)

Opioid-containing antitussives in Switzerland: a descriptive cross-sectional time-series analysis of pharmacy sales 2013–2022

Cite this as:
Swiss Med Wkly. 2025;155:4188
Published
25.06.2025

Summary

BACKGROUND: Opioid-containing antitussives are used to symptomatically treat a dry, irritative cough but bring a risk of misuse as recreational drugs. Since the update of the Swiss Therapeutic Products Act in 2019, opioid-containing antitussives are regulated more strictly, being available only on prescription and no longer over the counter.

AIM: This study aimed to describe the sales trends of opioid-containing antitussives in Switzerland between 2011 and 2022 to assess the impact of the regulation change.

METHODS: We descriptively analysed cross-sectional data of opioid sales from wholesalers to pharmacies and self-dispensing physicians as an indicator of community use.

MAIN FINDINGS: An estimated 369 million standard units of opioid-containing antitussives were sold over the whole observation period, of which 59% contained dextromethorphan as the active ingredient. Sales decreased slowly between 2011 and 2019, then dropped substantially in 2020 (−30.4% compared to previous year) and 2021 (−15.2%), then partially recovered in 2022. The sales of codeine-containing antitussives did not recover until the end of the study period (quarter 3 of 2022) and remained 37.3% lower than before the rescheduling (quarter 4 of 2018).

DISCUSSION: It is likely that repeated media attention on cases of misuse of opioid-containing antitussives led to more cautious dispensing in Switzerland leading up to the revision of the Therapeutic Products Act in 2019. The substantial decrease in sales in 2020 and 2021 was likely related to the COVID-19 pandemic rather than the rescheduling of opioid-containing antitussives. Longer data collection will be needed to assess the impact of the regulation change post-pandemic.

References

  1. Eickhoff C, Hämmerlein A, Griese N, Schulz M. Nature and frequency of drug-related problems in self-medication (over-the-counter drugs) in daily community pharmacy practice in Germany. Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):254–60. 10.1002/pds.2241
  2. Krüger K, Gehrke-Beck S, Holzinger F, Heintze C. S3-Leitlinie Akuter und chronischer Husten. AWMF online. 2021. Available from: https://register.awmf.org/de/leitlinien/detail/053-013
  3. Burns JM, Boyer EW. Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov;4:75–82. 10.2147/SAR.S36761
  4. Bachmann A, Galgano L, Guillaume M. Jugendliche mit Medikamenten- und Mischkonsum: Situations- und Bedarfsanalyse. Infodrog. 2022. Available from: https://www.infodrog.ch/files/content/ff-de/Bericht_Jugendliche%20Mischkonsum%20Situationsanalsyse%20und%20Empfehlungen.pdf
  5. Quednow BB, Steinhoff A, Bechtiger L, Ribeaud D, Eisner M, Shanahan L. High Prevalence and Early Onsets: Legal and Illegal Substance Use in an Urban Cohort of Young Adults in Switzerland. Eur Addict Res. 2022;28(3):186–98. 10.1159/000520178
  6. Steinhoff A, Shanahan L, Bechtiger L, Zimmermann J, Ribeaud D, Eisner MP, et al. When Substance Use Is Underreported: Comparing Self-Reports and Hair Toxicology in an Urban Cohort of Young Adults. J Am Acad Child Adolesc Psychiatry. 2023 Jul;62(7):791–804. 10.1016/j.jaac.2022.11.011
  7. Journey JD, Agrawal S, Stern E. Dextromethorphan Toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023., Available from https://www.ncbi.nlm.nih.gov/books/NBK538502/
  8. Weier M, Weier N, O’Mara B. Over-the-Counter Medications and Their Misuse: A Focus on Codeine. In: Patel VB, Preedy VR, editors. Handbook of Substance Misuse and Addictions. Cham: Springer International Publishing; 2022. pp. 1–23.
  9. Die Bundesversammlung der Schweizerischen Eidgenossenschaft. Bundesgesetz über Arzneimittel und Medizinprodukte. 2002. Available from: https://www.fedlex.admin.ch/eli/cc/2001/422/de
  10. Bundesamt für Gesundheit Erleichterte Abgabe von Arzneimitteln der Liste B. https://www.bag.admin.ch/bag/de/home/medizin-und-forschung/heilmittel/abgabe-von-arzneimitteln.html
  11. Swissmedic. Revision des Heilmittelrechts – Liste der von der Abgabekategorie C in die Abgabekategorie B umgeteilten Arzneimittel. Swissmedic 2019. Available from: https://www.swissmedic.ch/swissmedic/de/home/news/mitteilungen/liste_abgabekategorie_c_abgabekategorie_bumgeteilten_am.html
  12. Bundesamt für Statistik. Struktur der ständigen Wohnbevölkerung nach Kanton, 1999-2022. BAS. 2023. Available from: https://www.bfs.admin.ch/asset/de/26565154
  13. Suda KJ, Kim KC, Hernandez I, Gellad WF, Rothenberger S, Campbell A, et al. The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. J Am Pharm Assoc (Wash DC). 2022;62(3):766–774.e6. 10.1016/j.japh.2021.12.014
  14. Bundesrat. Bundesgesetz über die Bekämpfung übertragbarer Krankheiten des Menschen. 2012. Available from: https://www.fedlex.admin.ch/eli/cc/2015/297/de
  15. Bundesrat. Coronavirus: Bundesrat verbietet grosse Veranstaltungen. 2020. Available from: https://www.admin.ch/gov/de/start/dokumentation/medienmitteilungen.msg-id-78289.html
  16. Bundesrat. Coronavirus: Rückkehr in die normale Lage und Planung der Übergangsphase bis Frühling 2023. 2022. Available from: https://www.admin.ch/gov/de/start/dokumentation/medienmitteilungen.msg-id-87801.html
  17. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022.
  18. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer; 2016.
  19. Hyndman RJ, Khandakar Y. Automatic time series forecasting: the forecast package for {R}. J Stat Softw. 2008;27(3):1–22. 10.18637/jss.v027.i03
  20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct;370(9596):1453–7. 10.1016/S0140-6736(07)61602-X
  21. European Medicines Agency. Codeine not to be used in children below 12 years for cough and cold. 2015. Available from: https://www.ema.europa.eu/en/news/codeine-not-be-used-children-below-12-years-cough-and-cold
  22. Swissmedic. Husten- und Erkältungsmittel mit Codein bzw. Dihydrocodein: Anpassungen der Arzneimittelinformationen. 2017. Available from: https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/archiv/hpc-husten-und-erkaeltungsmittel-mit-codein-bzw-dihydrocodein.html
  23. Morice A, Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Respir Res. 2016 Aug;3(1):e000137. 10.1136/bmjresp-2016-000137
  24. Oh S, Agrawal S, Sabir S, Taylor A. Dextromethorphan. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024., Available from https://www.ncbi.nlm.nih.gov/books/NBK538216/
  25. Schnyder M. Medikamenten-Missbrauch - Hustensirup mit Codein: Was gilt nun ab Januar? In: Schweiz. Radio Fernseh. 2018. Available from: https://www.srf.ch/sendungen/kassensturz-espresso/medikamenten-missbrauch-hustensirup-mit-codein-was-gilt-nun-ab-januar
  26. Wermelinger R. Medikamenten-Missbrauch - Hustensaft als Partydroge: Kommt die Rezeptpflicht? In: Schweiz. Radio Fernseh. 2018. Available from: https://www.srf.ch/news/schweiz/medikamenten-missbrauch-hustensaft-als-partydroge-kommt-die-rezeptpflicht
  27. Roth S. Missbrauch: Mit Hustensirup zum Rausch. In: St Galler Tagblatt. 2018. Available from: https://www.tagblatt.ch/ostschweiz/appenzellerland/missbrauch-mit-hustensirup-zum-rausch-ld.606519
  28. 20 Minuten. Jugendliche dröhnen sich mit Hustensaft zu. In: 20 Minuten. 2018. Available from: https://www.20min.ch/story/jugendliche-droehnen-sich-mit-hustensaft-zu-190224395258
  29. Tox Info Suisse. Jahresbericht 2020. Availabe from: https://www.toxinfo.ch/customer/files/878/9211581_Tox_JB-2020_DE_Web.pdf
  30. Bundesamt für Gesundheit BAG. Infoportal übertragbare Krankheiten: Influenza (Grippe). Available from: https://idd.bag.admin.ch/diseases/influenza/statistic
  31. drugshortage.ch. Lieferengpässe von Medikamenten - Abgeschlossen. Available from: https://www.drugshortage.ch/index.php/abgeschlossen/
  32. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459–68. 10.1038/s41586-020-2286-9
  33. Healy M. Why you should avoid some cough syrups if you think you’ve got the coronavirus. In: Los Angel. Times. 2020. Available from: https://www.latimes.com/science/story/2020-04-30/why-you-should-avoid-cough-syrup-if-you-think-youve-got-the-coronavirus
  34. Zimmer C. Old Drugs May Find a New Purpose: Fighting the Coronavirus. In: N. Y. Times. 2020. Available from: https://www.nytimes.com/2020/04/30/health/coronavirus-antiviral-drugs.html
  35. Hüttemann D. Nature-Studie: Neue Kandidaten gegen Coronaviren und Warnung vor Dextromethorphan. In: Pharm. Ztg. Online. 2020. Available from: https://www.pharmazeutische-zeitung.de/neue-kandidaten-gegen-coronaviren-und-warnung-vor-dextromethorphan-117321/
  36. HCI Solutions AG Compendium. R05DB13 Butamirat. Available from: https://compendium.ch/de/register/atc/R05DB13
  37. Ju C, Wei L, Man KK, Wang Z, Ma TT, Chan AY, et al. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. Lancet Public Health. 2022 Apr;7(4):e335–46. 10.1016/S2468-2667(22)00013-5
  38. Ministère du Travail de la Santé et des Solidarités. Agnès Buzyn décide d’inscrire la codéine et d’autres dérivés de l’opium à la liste des médicaments disponibles uniquement sur ordonnance. 2017. Available from: https://sante.gouv.fr/archives/archives-presse/archives-communiques-de-presse/article/agnes-buzyn-decide-d-inscrire-la-codeine-et-d-autres-derives-de-l-opium-a-la
  39. Natali I. Economic Opportunity and Opioid Regulation: the Case of Codeine in France. Toulouse School of Economics (TSE). 2024. Working paper 24-1563. Available from: https://www.tse-fr.eu/publications/economic-opportunity-and-opioid-regulation-case-codeine-france
  40. Richards GC, Aronson JK, MacKenna B, Goldacre B, Hobbs FD, Heneghan C. Sales of Over-the-Counter Products Containing Codeine in 31 Countries, 2013-2019: A Retrospective Observational Study. Drug Saf. 2022 Mar;45(3):237–47. 10.1007/s40264-021-01143-2